mmune Checkpoint Inhibitors for Advanced Melanoma: 10-Year Outcomes Turn Heads
Source: Medscape, January 2025
The final, 10-year results of the international randomised clinical trial known as CheckMate 067 report that the median overall survival with advanced melanoma is nearly 72 months with the combination of nivolumab + ipilimumab, nearly 37 months with nivolumab monotherapy, and only 20 months with ipilimumab monotherapy. Both agents are immune checkpoint inhibitors, but their immune targets differ.
METHODOLOGY:
• A double-blinded, phase 3, randomised clinical trial (CheckMate 067) comparing nivolumab + ipilimumab (n = 314) vs monotherapy with either nivolumab (n = 316) or ipilimumab (n = 315) and comparing one monotherapy to the other.
• The primary outcomes were overall survival and progression-free survival